{"id":44739,"date":"2022-06-06T13:01:29","date_gmt":"2022-06-06T11:01:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/adicet-bio-reports-emerging-data-from-adi-001-phase-1-trial-at-the-american-society-of-clinical-oncology-annual-meeting\/"},"modified":"2022-06-06T13:01:29","modified_gmt":"2022-06-06T11:01:29","slug":"adicet-bio-reports-emerging-data-from-adi-001-phase-1-trial-at-the-american-society-of-clinical-oncology-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/adicet-bio-reports-emerging-data-from-adi-001-phase-1-trial-at-the-american-society-of-clinical-oncology-annual-meeting\/","title":{"rendered":"Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting"},"content":{"rendered":"
\n

\nADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed\/refractory high grade aggressive Non-Hodgkin\u2019s Lymphoma (NHL)<\/i>, a<\/i>s of May 31, 2022 data-cut date<\/i>\n<\/p>\n

\n80% ORR and CR rate at dose levels 2 and 3 combined<\/i>\n<\/p>\n

\n100% ORR<\/i> and CR rate in three anti-CD19 CAR-T relapsed patients<\/i>\n<\/p>\n

\n50% of evaluable patients with at least six months follow-up remain cancer free<\/i>\n<\/p>\n

\nDose-related increase of ADI-001 exposure <\/i>observed in blood<\/i>\n<\/p>\n

\nCompany expects to identify recommended Phase 2 dose in second half of 2022 and initiate at least one potentially pivotal <\/i>study in first half of 2023<\/i>\n<\/p>\n

\nCompany to host webcast today at 1:30pm PT \/ 4:30pm ET<\/i>\n<\/p>\n

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced emerging positive safety and efficacy data from the Company\u2019s Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin\u2019s Lymphoma (NHL) in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 6, 2022. The presentation outlines a summary of clinical data as of a May 31, 2022, data-cut date.\n<\/p>\n

<\/a><\/p>\n

\n\u201cAdicet is a pioneer in the field of gamma delta CAR T cell therapies and it is gratifying to see the highly encouraging clinical data for ADI-001 unfold as a potential best-in-class therapy for NHL,\u201d said Chen Schor, President and Chief Executive Officer of Adicet Bio. \u201cNotably, with a favorable safety and tolerability profile, treatment to date with ADI-001 demonstrated an impressive CR rate, including 100% in CAR-T relapsed patients, and very encouraging durability of response. We look forward to discussing the data in more detail and outlining next steps in our webcast this afternoon.\u201d\n<\/p>\n

\n\u201cIt is impressive to see 50 percent of six-month evaluable patients cancer free beyond seven months. One of these patients had previously relapsed after two treatments with autologous anti-CD19 CAR T and now remains cancer free seven and a half months following administration of ADI-001, suggesting the patient has had major clinical benefit from ADI-001. This is particularly notable because patients who relapse after autologous anti-CD19 CAR T have dismal outcomes with a median survival of approximately six months,\u201d said Sattva Neelapu, M.D., Professor in the Department of Lymphoma\/Myeloma at The University of Texas MD Anderson Cancer Center. \u201cWhen we look at the totality of these early data, we have an indicator that allogeneic gamma-delta CAR T cell therapy like ADI-001 could be a significant advance.\u201d\n<\/p>\n

\n\u201cNHL remains a disease that is very difficult to treat, especially in high-risk patients with aggressive disease. Our study is enrolling patients with aggressive B-cell lymphoma, including patients with double-hit and triple-hit high-grade B cell lymphoma and patients who had a prior relapse to autologous anti-CD19 CAR T therapy,\u201d said Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio. \u201cWe are encouraged by the CRs observed to date in the Phase 1 study and are committed to rapidly advancing ADI-001 into a potential pivotal program.\u201d\n<\/p>\n

\nData highlights as of the May 31, 2022 data-cut date included in the ASCO presentation are as follows:\n<\/p>\n